Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2413818 | 0.79 | MAPK1 (0.42) | MEN1KMT2ATSHRMAPK1LMNA | |
| SCHEMBL26307212 | 0.78 | APLNR (0.40) | APLNRMAPK1ALDH1A1MAPT | |
| SCHEMBL27490666 | 0.78 | MAPK1 (0.41) | APLNRMEN1KMT2ATSHRMAPK1 | |
| SCHEMBL17319374 | 0.78 | KDM4E (0.37) | MEN1KMT2ATSHRMAPK1HTT | |
| SCHEMBL15853710 | 0.77 | NR3C2 (0.40) | LMNATP53HTTPDE2A | |
| SCHEMBL15130833 | 0.77 | APLNR (0.56) | APLNRLMNAALDH1A1PDE2A | |
| SCHEMBL2497862 | 0.76 | APLNR (0.46) | APLNRMEN1KMT2ATSHRMAPK1 | |
| SCHEMBL2698362 | 0.76 | PDE2A (0.55) | MEN1KMT2ATSHRMAPK1LMNA | |
| SCHEMBL9910111 | 0.76 | PDE2A (0.55) | MEN1KMT2ATSHRMAPK1LMNA | |
| SCHEMBL2004602 | 0.76 | LMNA (0.64) | APLNRMEN1KMT2ATSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3243515-B1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2019-10-16 | — | — | EP | disclosed |
| EP-3169684-B1 | COMBINATION OF KMO INHIBITOR 6-(3-CHLORO-4-CYCLOPROPOXYPHENYL)PYRIMIDINE-4-CARBOXYLIC ACID WITH ANTIVIRAL AGENT FOR TREATING HIV RELATED NEUROLOGICAL DISORDERS | CHDI FOUNDATION INC (US) | 2019-06-26 | — | — | EP | disclosed |
| US-9981918-B2 | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| EP-3243515-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI Foundation, Inc. (US) | 2017-11-15 | — | — | EP | disclosed |
| US-20170209440-A1 | METHODS AND COMPOSITIONS FOR TREATING HIV-RELATED DISORDERS | CHDI FOUNDATION, INC. | 2017-07-27 | — | — | US | disclosed |
| US-20170209440-A1 | METHODS AND COMPOSITIONS FOR TREATING HIV-RELATED DISORDERS | CHDI FOUNDATION, INC. | 2017-07-27 | — | — | US | disclosed |
| EP-2750677-B1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20160251318-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2016-09-01 | — | — | US | disclosed |
| US-20160251318-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2016-09-01 | — | — | US | disclosed |
| WO-2016011316-A1 | METHODS AND COMPOSITIONS FOR TREATING HIV-RELATED DISORDERS | CHDI FOUNDATION, INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| WO-2013033085-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | COURTNEY STEPHEN MARTIN (GB) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251318-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | KMO, KYNU, HAAO | APLNR 2238/4885MEN1 1936/4885KMT2A 107/4885 |
| US-20170209440-A1 | METHODS AND COMPOSITIONS FOR TREATING HIV-RELATED DISORDERS | KMO, KYNU, PNPO | APLNR 3153/4885MEN1 2856/4885KMT2A 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.